{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.98","upperLimit":"12.42","value":"8.31"},{"groupId":"OG001","lowerLimit":"14.06","upperLimit":"31.11","value":"21.75"},{"groupId":"OG002","lowerLimit":"8.77","upperLimit":"16.56","value":"12.45"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"54"},{"groupId":"OG002","value":"134"}],"units":"Participants"}],"description":"Duration of response (DOR) was defined as the time from first documented response (partial response (PR) or complete response (CR)) to the date of first documented disease progression (PD) or death due to any cause, among patients with a confirmed PR or CR per RECIST 1.0.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with ALK-translocated NSCLC who were previously treated with an ALK inhibitor.","id":"OG000","title":"NSCLC With Prior ALKi (Arms 1A + 1B)"},{"description":"Patients with ALK-translocated NSCLC not previously treated with an ALK inhibitor.","id":"OG001","title":"NSCLC ALKi Naive (Arm 2)"},{"description":"all NSCLC patients.","id":"OG002","title":"All NSCLC"}],"paramType":"MEDIAN","populationDescription":"Full analysis set (FAS) - NSCLC: Subset of Full Analysis Set including ALK-positive NSCLC patients who received at least one dose of LDK378 in the 750 mg dose group and had a confirmed overall complete response or partial response after initiation of LDK378.","reportingStatus":"POSTED","timeFrame":"275 weeks","title":"Duration of Response (DOR) Based on BIRC","type":"SECONDARY","unitOfMeasure":"months"}